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OBJECTIVE: The development of osteoporosis is associated with several risk factors, such as genetic structures that
affect bone turnover and bone mass. The impact of genetic structures on osteoporosis is not known. Plasminogen
activator inhibitor type-1 regulates the bone matrix and bone balance. This study assessed the correlation between
plasminogen activator inhibitor type-1 gene 4G/5G polymorphisms and osteoporosis in a population of Turkish
women.
METHODS: A total of 195 postmenopausal female patients who were diagnosed with osteoporosis (Group I) based
on bone mineral density measurements via dual-energy x-ray absorptiometry and 90 females with no osteoporosis
(Group II) were included in this study. Correlations between PAI-1 gene 4G/5G polymorphisms and osteoporosis
were investigated through the identification of PAI-1 gene 4G/5G polymorphism genotypes using the polymerase
chain reaction.
RESULTS: No significant differences in the genotype and allele frequency of 4G/5G plasminogen activator inhibitor
type-1 polymorphisms were observed between the two groups, and both groups exhibited the most frequently
observed 4G5G genotype.
CONCLUSION: No correlation between the development of osteoporosis in the female Turkish population and 4G/
5G plasminogen activator inhibitor type-1 gene polymorphisms was observed.
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INTRODUCTION
Osteoporosis is a systemic skeletal disease that is
characterized by an increase in bone fragility due to a
decrease in bone mass and the deterioration of bone
microarchitecture (1). This disease is especially prevalent
in the elderly population, and it is a significant public health
issue that reduces patient functioning and quality of life. An
improved understanding of the risk factors for osteoporosis
is important for the diagnosis, maintenance, and treatment
of this significant disease (2,3).
Several epidemiological and clinical studies have demon-
strated the importance of genetics in osteoporosis pathogenesis
(4-6). Genetic factors affect bone turnover and can result in the
reduction of bonemass to,50-80% (5-7). Gene polymorphisms
may contribute to osteoporosis and impact bone mineral
density (4-8).
Plasminogen activator inhibitor-1 (PAI-1) is a 50-kDa,
single-chain glycoprotein in the serine protease inhibitor
family (9). A plasminogen activation system (PAS) that was
initially identified in the fibrinolytic system, and its
fundamental inhibitor, PAI-1, regulate the bone matrix
and alter bone balance (10). PAI-1 primarily inhibits tissue-
type (tPa) and urokinase (uPa) plasminogen activators (11)
and reduces extracellular matrix destruction by decreasing
the plasmin-mediated activation of matrix metalloprotei-
nases (MMPs) (12).
Genetic factors predominantly determine plasma PAI-1
levels (13). The human PAI-1 gene contains various
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polymorphic loci in approximately 12.22 kb on chromosome
7q22. The 4G/5G insertion/deletion is the most investigated
polymorphism, which is 675 base pairs (bp) upstream of the
transcriptional start site. This polymorphism regulates the
expression of the PAI-1 gene (9,13,14).
The correlation of the PAI-1 4G/5G insertion/deletion
polymorphism with several diseases, such as coronary
artery disease, asthma, hypertension, stroke, obesity, rheu-
matoid arthritis, and osteoarthritis, has been investigated
previously (15-21). However, the contribution of PAI-1
insertion/deletion variations (4G/5G) to osteoporosis has
not been investigated in the Turkish population. This study
investigated the correlation between PAI-1 gene poly-
morphisms and osteoporosis in Turkish females.
MATERIALS AND METHODS
Subjects
Postmenopausal females who were admitted to the
Osteoporosis Clinic of the Physical Medicine and Rehabi-
litation Department of Eskisehir Osmangazi University
(Turkey) were informed of the study, and patients who opted
for inclusion in the study were evaluated. Patients who were
diagnosed with parathyroid, thyroid, liver, and rheumatolo-
gical diseases that affect bone metabolism; patients with a
history of malignancy or surgically induced menopause; and
patients who used drugs affecting bone metabolism (e.g.,
corticosteroids, anticonvulsants, and heparin) during the
clinical and laboratory assessments were excluded from the
study. Erythrocyte sedimentation rate, complete blood count,
serum alkaline phosphatase, calcium, phosphorous, serum
glutamic oxaloacetic transaminase, serum glutamic pyruvic
transaminase, gamma-glutamyl transpeptidase, blood urea
nitrogen, creatinine, glucose, uric acid, albumin, total protein,
urine calcium/creatinine, thyroid-stimulating hormone, para-
thyroid hormone, cortisol and vitamin D levels were
measured prior to the study. A total of 285 patients satisfied
the study criteria and were included in the study. The age,
height, weight, and bodymass index (BMI) of the participants
were evaluated. All participants underwent dual-energy x-
ray absorptiometry (DEXA) evaluations, and 195 postmeno-
pausal females were diagnosed with osteoporosis based on
this assessment (Group I). Ninety patients without osteo-
porosis were included in the control group (Group II). All
participants provided informed consent in compliance with
the study protocol (#2009/229), which was approved by the
Ethics Committee of the Medical Faculty of Eskisehir
Osmangazi University (Turkey).
Bone mineral density
The participants underwent DEXA scanning using a
Hologic QDR 4500 W system (Hologic, Inc., Bedford,
USA) to assess bone mineral density (BMD), and the lumbar
spine (vertebrae L1-L4) and hip (femur neck) were
evaluated. Patients with a mean bone density below 2.5
SD were diagnosed with osteoporosis, as recommended by
the World Health Organization (WHO).
Sample collection and determination of PAI-1
genotypes
Genomic DNA isolation was performed using the salt-
extraction method in 10 ml of peripheral blood that was
collected in EDTA tubes for the analysis of 4G/5G
polymorphisms in the promoter region of PAI-1. The
obtained genomic DNA was maintained at 4 C˚. The PAI-1
polymorphism gene region was amplified in a thermal
cycler (Sacem Life Technologies, Peltier-based Thermal
Cycler SCM 96G, Turkey) using 25 ml of a PCR mixture
containing 0.5 ml DNA, 10X PCR Buffer (Biolabs, New
England), 0.2 mmol/L dNTPs (Sigma, Germany), 1.25 U
Taq polymerase (Biolabs, New England), 50 pmol of 4G- or
5G-specific primer, 50 pmol of downstream primer, and
2.5 pmol of upstream primer. The following primers
(Metabion, Germany) were used: 5’-GTC TGG ACA CGT
GGG GG-3’ for the 5G allele, 5’-GTC TGG ACA CGT GGG
GA-3’ for the 4G allele, 5’-TGC AGC CAG CCA CGT GAT
TGT CTA G-3’ for the downstream primer, and 5’-AAG
CTT TTA CCA TGG TAA CCC CTG GT-3’ for the upstream
primer (positive control). The PCR mixture was subjected to
35 cycles for 60 sec at 94 C˚, 30 sec at 54 C˚, and 40 sec at 72 C˚
following the initial denaturation for 3 min at 94 C˚. These
PCR products were processed in 2% agarose gel and
analyzed under UV light (Labwork, Cambridge, United
Kingdom). The 4G and 5G alleles were defined according to
a 139-bp DNA fragment of the general downstream primer
that was produced during the PCR process. Samples that
produced a 139-bp band from the 4G primer and that did
not produce a 139-bp band from the 5G primer were
considered a homozygous 4G genotype. Samples that
produced a 139-bp band from the 5G primer but that did
not produce a 139-bp band from the 4G primer were
considered a homozygous 5G genotype. Samples that
produced a 139-bp band from both primers were considered
a heterozygous 4G5G genotype.
Statistical analysis
The data were evaluated using SPSS Version 20 software
(IBM Corp. Armonk, New York, USA). The continuous
variables were not normally distributed based on the
Shapiro-Wilk test for normality. The Mann-Whitney U test
was implemented for the comparison of the two groups.
Medians (quartiles) are provided as descriptive statistics.
The Pearson chi-square test was conducted for categorical
variables. N and % values are provided. A p,0.05 was
considered statistically significant.
RESULTS
This study investigated the effect of the PAI-1 gene 4G/
5G polymorphisms on the development of osteoporosis in
Turkish women. The study groups are listed in Table 1. No
significant differences in the genotype and allele frequency
of the 4G/5G PAI-1 polymorphism were observed between
the groups (p= 0.619 and p=0.361, respectively). However,
the most frequent genotype, 4G5G, was observed in both
groups. The 4G5G genotype was 39.49% in Group I and
42.22% in Group II. The 4G and 5G allele frequencies ranged
from 47.4 - 52.6% in Group I and 43.3 - 56.7% in Group II.
DISCUSSION
Osteoporosis is characterized by low bone mass, an
increase in bone fragility, deterioration in bone microarch-
itecture, and an increase in the risk of fracture (1). Some
metabolic changes, such as those that occur due to a lack of
estrogen, immobilization, metabolic acidosis, hyperpar-
athyroidism, and systemic and local inflammatory diseases,
affect the osteoclast count and activity associated with bone
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turnover (22). Prostaglandins, insulin-like growth factors
(IGFs), interleukins (IL-1, IL-6, and IL-11), tumor necrosis
factor (TNF), and several local factors in bone, such as
transforming growth factor (TGF), also contribute to the
regulation of bone formation and resorption (22,23).
TGF-b is an anabolic factor that increases extracellular
matrix production and the expression of various types of
collagen and proteoglycans (24,25). TGFb1 polymorphisms
may be significantly relevant in BMD and the occurrence of
fracture (24,26). PAI-1 is known to have a regulatory effect
on matrix components, including TGF-b, matrix c-carbox-
yglutamic acid (Gla) protein, and osteocalcin. Therefore,
PAI-1 may affect bone matrix biology and significantly
regulate bone remodeling (10). PAI-1 levels are regulated by
a 4G/5G insertion/deletion polymorphism (13).
This study investigated the relationship of the 4G/5G
polymorphism, which regulates PAI-1 as an inhibitor of the
plasminogen activator system, with osteoporosis in Turkish
women.
A relationship between the PAI-1 4G/5G gene poly-
morphism and diseases, such as coronary artery disease,
hypertension, stroke, and obesity, has been reported
previously, but this polymorphism is not related to asthma,
rheumatoid arthritis, and osteoarthritis (15-21). Genetic
variations occur in populations. Previous studies have
investigated the PAI-1 4G/5G insertion/deletion poly-
morphism in the Turkish population, but its relationship
with osteoporosis has not been investigated; this relation-
ship was examined in our study for the first time.
No differences in the PAI-1 4G/5G genotype were
observed between the postmenopausal osteoporotic patients
and the healthy control group. The role of common
variations of COLIA-1, TGFb-1, and PAI-1 genes in early
postmenopausal osteoporotic Caucasians and healthy
women was previously investigated by Hubacek et al.,
who observed no significant difference in the PAI-1 4G/5G
genotype between osteoporotic patients and the healthy
control group, which is consistent with our study. However,
the 4G4G genotype was more common in the osteoporotic
patient group compared with the control group (27).
Our results suggest that the 4G/5G PAI-1 polymorphism
cannot be used as a marker for the development of
osteoporosis in Turkish women. However, this result may
not be applicable to all populations when gene pools,
lifestyles, and gene-environment interactions in various
populations are considered. Therefore, multi-centered stu-
dies on different populations and in different gene regions
in larger samples are required to establish the correlation
between the 4G/5G PAI-1 polymorphism and osteoporosis.
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